Diabetic Kidney Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cameron, 2006, The discovery of diabetic nephropathy: From small print to centre stage, J Nephrol, 19, S75
Reutens, 2013, Epidemiology of diabetic kidney disease, Med Clin North Am, 97, 1, 10.1016/j.mcna.2012.10.001
de Boer, 2011, Temporal trends in the prevalence of diabetic kidney disease in the United States, JAMA, 305, 2532, 10.1001/jama.2011.861
Menke, 2015, Prevalence of and trends in diabetes among adults in the United States, 1988-2012, JAMA, 314, 1021, 10.1001/jama.2015.10029
Flegal, 1998, Overweight and obesity in the United States: Prevalence and trends, 1960-1994, Int J Obes Relat Metab Disord, 22, 39, 10.1038/sj.ijo.0800541
Flegal, 2016, Trends in obesity among adults in the United States, 2005 to 2014, JAMA, 315, 2284, 10.1001/jama.2016.6458
Lozano, 2012, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2095, 10.1016/S0140-6736(12)61728-0
Jha, 2013, Chronic kidney disease: Global dimension and perspectives, Lancet, 382, 260, 10.1016/S0140-6736(13)60687-X
Afkarian, 2013, Kidney disease and increased mortality risk in type 2 diabetes, J Am Soc Nephrol, 24, 302, 10.1681/ASN.2012070718
Caramori, 2013, Renal lesions predict progression of diabetic nephropathy in type 1 diabetes, J Am Soc Nephrol, 24, 1175, 10.1681/ASN.2012070739
1995, Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial, Kidney Int, 47, 1703, 10.1038/ki.1995.236
1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
Tonna, 2010, Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms, Nat Rev Nephrol, 6, 332, 10.1038/nrneph.2010.55
Nathan, 2014, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview, Diabetes Care, 37, 9, 10.2337/dc13-2112
de Boer, 2011, Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes, N Engl J Med, 365, 2366, 10.1056/NEJMoa1111732
Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470
Bilous, 2008, Microvascular disease: What does the UKPDS tell us about diabetic nephropathy?, Diabet Med, 25, 25, 10.1111/j.1464-5491.2008.02496.x
Retnakaran, 2006, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74, Diabetes, 55, 1832, 10.2337/db05-1620
Bakris, 2003, Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study, Arch Intern Med, 163, 1555, 10.1001/archinte.163.13.1555
Pohl, 2005, Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations, J Am Soc Nephrol, 16, 3027, 10.1681/ASN.2004110919
Fioretto, 2007, Histopathology of diabetic nephropathy, Semin Nephrol, 27, 195, 10.1016/j.semnephrol.2007.01.012
Tyagi, 2008, Thickness of glomerular and tubular basement membranes in preclinical and clinical stages of diabetic nephropathy, Indian J Nephrol, 18, 64, 10.4103/0971-4065.42336
Drummond, 2002, The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes, Diabetes, 51, 1580, 10.2337/diabetes.51.5.1580
Osterby, 2001, Renal structures in type 2 diabetic patients with elevated albumin excretion rate, APMIS, 109, 751, 10.1034/j.1600-0463.2001.d01-142.x
Saito, 1988, Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions, Kidney Int, 34, 389, 10.1038/ki.1988.193
Stout, 1993, Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule, Hum Pathol, 24, 77, 10.1016/0046-8177(93)90066-P
Fioretto, 2008, The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007, Diabetologia, 51, 1347, 10.1007/s00125-008-1051-7
Tervaert, 2010, Pathologic classification of diabetic nephropathy, J Am Soc Nephrol, 21, 556, 10.1681/ASN.2010010010
Mogensen, 1983, The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy, Diabetes, 32, 64, 10.2337/diab.32.2.S64
Adler, 2003, Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x
Gaede, 2004, Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria, Nephrol Dial Transplant, 19, 2784, 10.1093/ndt/gfh470
Pacilli, Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative [published online ahead of print December 9, 2016], Diabetes Metab Res Rev
Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA, 316, 602, 10.1001/jama.2016.10924
Klessens, 2016, An autopsy study suggests that diabetic nephropathy is underdiagnosed, Kidney Int, 90, 149, 10.1016/j.kint.2016.01.023
Thomas, 2006, Anaemia in diabetes: Is there a rationale to TREAT?, Diabetologia, 49, 1151, 10.1007/s00125-006-0215-6
Moseley, 2012, Type 2 diabetes and bone fractures, Curr Opin Endocrinol Diabetes Obes, 19, 128, 10.1097/MED.0b013e328350a6e1
Foley, 2009, Why is the mortality of dialysis patients in the United States much higher than the rest of the world?, J Am Soc Nephrol, 20, 1432, 10.1681/ASN.2009030282
Tuttle, 1992, Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes, Kidney Int, 42, 167, 10.1038/ki.1992.274
Tuttle, 1991, Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus, N Engl J Med, 324, 1626, 10.1056/NEJM199106063242304
Tuttle, 2002, Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes, Am J Physiol Renal Physiol, 282, F103, 10.1152/ajprenal.00155.2001
Grabias, 2014, The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney homeostasis, Am J Physiol Renal Physiol, 306, F473, 10.1152/ajprenal.00503.2013
Premaratne, 2015, The impact of hyperfiltration on the diabetic kidney, Diabetes Metab, 41, 5, 10.1016/j.diabet.2014.10.003
Tuttle, 2017, Back to the future: Glomerular hyperfiltration and the diabetic kidney, Diabetes, 66, 14, 10.2337/dbi16-0056
Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887
2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4
Tuttle, 2014, Diabetic kidney disease: A report from an ADA consensus conference, Diabetes Care, 37, 2864, 10.2337/dc14-1296
2012, KDOQI clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005
Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987
Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743
Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431
Papademetriou, 2015, Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes, Kidney Int, 87, 649, 10.1038/ki.2014.296
Wong, 2016, Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON, Diabetes Care, 39, 694, 10.2337/dc15-2322
Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, Lancet, 376, 419, 10.1016/S0140-6736(10)60576-4
James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939
Perkovic, 2015, Redefining blood-pressure targets--SPRINT starts the marathon, N Engl J Med, 373, 2175, 10.1056/NEJMe1513301
Cushman, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286
Rocco, 2016, A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists, Kidney Int, 89, 261, 10.1016/j.kint.2015.12.024
Tuttle, 2005, The effect of ruboxistaurin on nephropathy in type 2 diabetes, Diabetes Care, 28, 2686, 10.2337/diacare.28.11.2686
Brosius, 2016, JAK inhibition in the treatment of diabetic kidney disease, Diabetologia, 59, 1624, 10.1007/s00125-016-4021-5
Navarro-González, 2015, Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial, J Am Soc Nephrol, 26, 220, 10.1681/ASN.2014010012
de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830
Bakris, 2015, Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial, JAMA, 314, 884, 10.1001/jama.2015.10081
Pfeffer, 2015, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, N Engl J Med, 373, 2247, 10.1056/NEJMoa1509225
Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827
Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 375, 1834, 10.1056/NEJMoa1607141
Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720
Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920
Gregg, 2014, Changes in diabetes-related complications in the United States, 1990-2010, N Engl J Med, 370, 1514, 10.1056/NEJMoa1310799
Maahs, 2013, Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study, Curr Diab Rep, 13, 550, 10.1007/s11892-013-0381-0
Bakris, 2015, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial, JAMA, 314, 884, 10.1001/jama.2015.10081